The business model of Cerus Corp revolves around developing and commercializing innovative systems for blood transfusion safety. Cerus Corp primarily focuses on the production of INTERCEPT Blood System, which is designed to minimize the risk of transfusion-transmitted infections. By providing pathogen inactivation technology, Cerus Corp ensures the safety and effectiveness of blood components for patients in need. With a commitment to improving global blood safety, Cerus Corp collaborates with blood centers, hospitals, and other healthcare institutions to implement their groundbreaking technology. Through its proactive approach, Cerus Corp aims to enhance the overall quality and access to safe blood transfusions worldwide.

Cerus Corp is primarily active in the healthcare industry.

The main competitors of Cerus Corp in the market include companies such as Grifols S.A., Baxter International Inc., and Terumo Corporation.

Cerus Corp is a medical device company founded in 1991. It specializes in developing and commercializing blood transfusion safety systems. With its flagship product, the INTERCEPT Blood System, Cerus Corp is dedicated to preventing the transmission of infectious diseases through blood transfusions. The innovative technology of the INTERCEPT Blood System helps in reducing the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. Cerus Corp has established collaborations with various blood centers and organizations worldwide to implement their solution and safeguard the blood supply. This California-based company continues to strive towards ensuring safer transfusions for patients globally.

Cerus Corp has achieved several significant milestones. The company's Intercept Blood System has received regulatory approvals in key markets, including the United States and Europe. This innovative technology has revolutionized blood safety by reducing the risk of transfusion-transmitted infections. Cerus Corp has also established successful collaborations with leading organizations, securing partnerships and licensing agreements to expand its market presence. Moreover, the company has conducted extensive clinical trials, demonstrating the safety and efficacy of its products. With a strong commitment to advancing medical advancements, Cerus Corp continues to make remarkable strides in improving the safety and availability of blood products worldwide.

Cerus Corp, a leading healthcare company, primarily operates in various countries and regions worldwide. With a global presence, the company's main operations can be found in North America, including the United States and Canada, where it is headquartered. Furthermore, Cerus Corp has an established footprint in Europe, particularly in countries like Germany, France, and the United Kingdom. Additionally, the company extends its reach to the Asia-Pacific region, encompassing countries such as Japan and Australia. Cerus Corp's international presence showcases its commitment to providing innovative solutions and services in transfusion medicine and blood safety on a global scale.

Cerus Corp represents a commitment to ensuring the safety of the global blood supply. With a strong corporate philosophy focused on innovation and collaboration, Cerus Corp strives to provide innovative solutions to enhance transfusion medicine. The company's values revolve around patient-centricity, quality, and integrity, ensuring the highest standards in product development and commercialization. By leveraging their cutting-edge technologies like the INTERCEPT Blood System, Cerus Corp aims to prevent the risk of transfusion-transmitted infections and improve patient outcomes. Through their dedication to safety and pioneering advancements, Cerus Corp continues to play a vital role in protecting lives through safer blood transfusions.

Analysts currently set an average price target of 4,76 USD for the Cerus stock (median: 5,10 USD), implying +65,9 % versus the latest price. The consensus is based on 10 analyst ratings.

Cerus Analyytikkojen kursstavoitteet 2026

10 analysts currently rate the Cerus stock: 8 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Cerus to generate revenue of 238,12 M USD and earnings per share of −0,03 USD.

Cerus Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Cerus share trades at 2,52 EUR (2,87 USD).

The Cerus share (CERS) is listed on 5 stock exchanges, including: NASDAQ (CERS), XETRA (CU2.DE), Frankfurt (CU2.F), Düsseldorf (CU2.DU), SIX (Zürich) (CU2.SW).

Cerus Corporation is a biomedical company specializing in the development and commercialization of products for virus inactivation and blood transfusion safety, as well as devices for plasmapheresis. The company was founded in 1991 and is headquartered in Concord, California, USA.

odotettu liikevaihto Cerus on 238,12 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Cerus on −5,76 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Cerus:n hinta-voitto-suhde (P/E) on tällä hetkellä −95,68. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Cerus-osakkeen arvostusta.

Cerus:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,32. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Cerus-osakkeen arvostuskennuslukuna.

Cerus:n Eulpool-laatuscore on 4/10.

Cerus:n ISIN on US1570851014. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Cerus:n WKN on 905249. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Cerus:n ticker on CERS. Tämä pörssinoteeraus käytetään Cerus-osakkeiden kauppaan pörssissä.

Cerus maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Cerus kuuluu sektoriin 'Terveydenhuolto'.

Cerus:n osingot jaetaan valuutassa USD.